HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA To Curtail Cosmetics Safety Work Under FY 2018 Budget Constraints

This article was originally published in The Rose Sheet

Executive Summary

President Trump's budget proposal for fiscal 2018 calls for "targeted reductions to the Food Safety program, including reducing staff levels through attrition." In its justification to congressional appropriators, FDA says it will reduce funding for cosmetics safety work in order to focus on top priorities in the broad foods area.

You may also be interested in...



FDA FY 2019 Budget Justification Light On Cosmetics Progam Details

There’s no new wealth of information on FDA’s cosmetics activities in its justification for proposed fiscal 2019 spending, potentially signaling that cosmetics will remain a low-priority area for the agency.

2017 In Review: FDA's Cosmetics Slowdown Could Bolster Case For Legislative Jumpstart

FDA's cosmetics activities fell off noticeably compared with 2016, and the change in the White House spurred the agency to begin looking for regulatory burdens to eliminate while shuffling priorities away from cosmetics to make do with proposed cuts in federal funding. In this climate, robust cosmetics oversight may depend on a legislative update, with multiple draft bills on the table.

FDA Puts Kibosh On Perfectly Posh For Unapproved Drug Claims

Perfectly Posh, which sells a colorful range of skin, hair and bath products online and through independent social sellers, draws an FDA warning letter for claims about acne, eczema and dandruff treatment, among others.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS109274

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel